

**Kevin Corbett** | Chief Executive Officer

J. Kevin Stitt | Governor

OHCA 2023-08

April 14, 2023

RE: Prior Authorization of Lucentis® – Effective 5/15/2023

Dear Provider:

As authorized by <u>OAC 317:30-5-77-2</u>, effective May 15, 2023, the Oklahoma Health Care Authority (OHCA) will require a prior authorization (PA) for LUCENTIS® (ranibizumab). The OHCA rules can be found at <a href="https://oklahoma.gov/ohca/policies-and-rules/xpolicy.html">https://oklahoma.gov/ohca/policies-and-rules/xpolicy.html</a>.

If a SoonerCare member has received LUCENTIS®, they will be allowed to continue. A PA form will be required for all SoonerCare members whether continuing or beginning therapy. Past dates of service **must** be noted on the form. PA form PHARM-18 is to be used for requests — forms can be found at <a href="https://www.okhca.org/rxforms">www.okhca.org/rxforms</a>.

BYOOVIZ™ (ranibizumab-nuna intravitreal injection) and CIMERLI™ (ranibizumab-eqrn intravitreal injection) are available without a PA.

The specific PA requirements for LUCENTIS® and other intravitreal implants are located on the OHCA website at <a href="www.okhca.org/pa">www.okhca.org/pa</a> in the Ocular/Otic therapeutic category.

## LUCENTIS® (Ranibizumab Intravitreal Injection) Approval Criteria:

- 1. An FDA-approved diagnosis; and
- 2. A patient-specific, clinically significant reason why the member cannot use BYOOVIZ (ranibizumab-nuna intravitreal injection) or CIMERLI™ (ranibizumab-eqrn intravitreal injection) must be provided. Biosimilars and/or reference products are preferred based on the lowest net cost product(s) and may be moved to either preferred or non-preferred if the net cost changes in comparison to the reference product and/or other available biosimilar products.







**Kevin Corbett** | Chief Executive Officer

J. Kevin Stitt | Governor

All medication PA requests must be submitted to the Pharmacy Prior Authorization Unit at the fax number located at the bottom of the PA form. Do not submit the request to the Medical Authorization Unit or via the provider portal.

If you have questions, please contact the pharmacy help desk at 800-522-0114, option 4.

Thank you for your continued service to Oklahoma's SoonerCare members.

Sincerely,

Traylor Rains

State Medicaid Director



